Scottsdale Drug-development company InNexus has been selected as one of the 2007 TSX Venture 50, a ranking of the top 10 venture capital companies in five industry sectors listed on the TSX Venture Exchange.

The TSX Venture 50 ranks the top ten companies across five categories of industry—life sciences, mining, oil and gas, technology, and diversified industries. The criteria used to determine the rankings include revenue, return on investment, market capitalization growth, and trading volume.

"There are over 2,000 companies listed on the TSX Venture Exchange and we are honored to be among the top 50," said Jeff Morhet, president and CEO of InNexus.

"We look forward to building InNexus into a world class developer of medicines to treat cancer and other hard-to-treat diseases and we appreciate our shareholders for recognizing our focus and commitment."

---

For more information:

InNexus news release, 06/20/2007